Correction to: Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis
Ricky Frazer, José Ángel Arranz, Sergio Vázquez Estévez, Omi Parikh, Laura-Maria Krabbe, Naveen S. Vasudev, Christian Doehn, Norbert Marschner, Tom Waddell, Will Ince, Peter J. Goebell
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsRenal cell carcinoma treatment · Economic and Financial Impacts of Cancer · Cancer Genomics and Diagnostics
Correction to: Current Oncology Reports (2024) 26:1639–1650
10.1007/s11912-024-01613-7
The original online version of this article was revised due to formatting errors introduced by the journal during typesetting.
-
Updates to the tables regarding bold emphasis and alignment have been made as shown below.
-
In the updated Figure 1 below, the spell-check markings (red underlines) have been removed.
The original article has been corrected.